menu
    • menu
    [{"orgOrder":0,"company":"Recipharm AB","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Recipharm AB \/ Bial","highestDevelopmentStatusID":"15","companyTruncated":"Recipharm AB \/ Bial"},{"orgOrder":0,"company":"Arranta Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Arranta Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arranta Bio \/ Recipharm AB","highestDevelopmentStatusID":"1","companyTruncated":"Arranta Bio \/ Recipharm AB"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ARCT-154","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Recipharm AB \/ Arcturus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Recipharm AB \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Recipharm AB \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Recipharm AB \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Vibalogics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vibalogics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vibalogics \/ Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Vibalogics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Erdosteine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recipharm AB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Recipharm AB \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Recipharm AB

    Menu

    Recipharm AB

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arranta Bio

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Arranta Bio

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Recipharm AB

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand Its Bi...

                            Details : The acquisition of Recipharm, to provide innovative drug developers in the Biologics market with differentiated contract development and manufacturing services for ATMPs and builds on the capabilities acquired through GenIbet transaction and acquisition ...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            February 18, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Recipharm AB

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAK-919

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Recipharm Announces Signature of letter of Intent for Aseptic Fill-Finish Manufacturing of Moderna’s COVID-1...

                            Details : Recipharm has reserved capacity to support the anticipated demand for the mRNA-1273 vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.

                            Product Name : mRNA-1273

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 24, 2020

                            Lead Product(s) : TAK-919

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erdosteine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recipharm’s Proprietary Molecule Erdosteine has been Positively Tested As Part of COVID-19 Treatment

                            Details : The study indicates that patients taking Erdosteine after hospital discharge benefit significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is one of the first to report HRQoL details in patients with COVID...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2020

                            Lead Product(s) : Erdosteine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARCT-154

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Arcturus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Recipharm Signs Agreement with Arcturus Therapeutics to Support the Manufacture of LUNAR[®]-COV19 (ARCT-021) ...

                            Details : Arcturus has secured manufacturing slots with Recipharm to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing phase 1/2 clinical trial.

                            Product Name : LUNAR-COV19

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 10, 2020

                            Lead Product(s) : ARCT-154

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Arcturus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vibalogics

                            Germany arrow
                            German Wound Congress
                            Not Confirmed

                            Vibalogics

                            Germany arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Johnson & Johnson

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vibalogics Announces Collaboration to Provide Additional Clinical Trial Material for COVID-19 Vaccine Candidat...

                            Details : Under the contract, Vibalogics will produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany, expected to yield thousands of vaccine doses.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 19, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Johnson & Johnson

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed

                            Recipharm AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opicapone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Bial

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API

                            Details : The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.

                            Product Name : Ongentys

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 10, 2020

                            Lead Product(s) : Opicapone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Bial

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth